Key Findings
Scientists at the Indiana University School of Medicine have discovered a method to reduce the formation of amyloid plaques, which are associated with Alzheimer’s disease and related dementias. In tests using an Alzheimer’s disease mouse model, the lead compound reduced amyloid peptide levels and amyloid precursor protein, resulting in a significant decrease in amyloid plaque burden in the brain. No physical or behavioral abnormalities were observed in the mice at the tested doses.
Technical Details
The research, published in Advanced Science, utilizes molecular glue degrader compounds. These compounds function by binding the interface of the amyloid precursor protein and its regulative protein within human neurons. This binding directs the amyloid precursor proteins into lysosomes—the cell’s natural disposal areas—for elimination. By targeting the proteins before they aggregate into plaques, this approach intervenes earlier in the disease process than current treatments that target plaques after they have already formed.
The development involved several specialized contributions:
- Anita Bellail, PhD, led the development of the molecular glue degrader library and targeted protein degradation methodologies.
- Sunghan Jung, PhD, utilized special neurons derived from Alzheimer’s patients and stem cell models to test the library and reveal the drug’s mechanism of action.
Background & Context
The project was funded by grants from the National Institute on Neurological Disorders and Stroke and the National Institute on Aging. To translate these findings into clinical applications, Chunhai Hao, MD, PhD, and Anita Bellail co-founded Degrome Therapeutics, a university-based startup.
Significance & Outlook
IU has filed and published a U.S. patent titled “Compounds and methods to treat Alzheimer’s disease.” While the early results are promising, researchers state that further work is required to improve the pharmacology and efficacy of the compounds. The long-term objective is to advance a lead compound into clinical trials for human patients to either stop the onset of Alzheimer’s disease or slow its progression.
Source: https://medicine.iu.edu/news/2026/10/alzhimers-plaque-treatment-compounds
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
